Clinical Trials Research
Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Published in Vaccine Weekly, November 24th, 2010
Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women worldwide.
Vaccination of the first study group has been completed and demonstrated that
PEV7 is safe and well-tolerated in all subjects and elicits an immune response even at low doses.
"This is an important step for both PEV7 and Pevion as we aim for proof of concept in humans with our innovative approach to disease management using a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2010-11-24)
More Articles from Vaccine Weekly
- Pediatric Vaccines
New pediatric vaccines study findings recently were reported by researchers at Manchester University - Pediatric Vaccines
Studies from University of Tokyo have provided new data on pediatric vaccines - Bacterial Vaccines
Data on bacterial vaccines described by researchers at Nationwide Children's Hospital - Vaccines
Data on vaccines reported by researchers at University Medical Center - Vaccines
Department of Health Encourages Pennsylvanians to Get Vaccinated for Flu - Vaccines
Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
